ATE466931T1 - Verbesserte adenovirusvektoren - Google Patents

Verbesserte adenovirusvektoren

Info

Publication number
ATE466931T1
ATE466931T1 AT97946337T AT97946337T ATE466931T1 AT E466931 T1 ATE466931 T1 AT E466931T1 AT 97946337 T AT97946337 T AT 97946337T AT 97946337 T AT97946337 T AT 97946337T AT E466931 T1 ATE466931 T1 AT E466931T1
Authority
AT
Austria
Prior art keywords
vectors
deleted
adenoviral
improved
gutted
Prior art date
Application number
AT97946337T
Other languages
English (en)
Inventor
Jeffrey Chamberlain
Andrea Amalfitano
Michael Hauser
Rajendra Kumar-Singh
Dennis Hartigan-O'connor
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE466931T1 publication Critical patent/ATE466931T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97946337T 1996-10-23 1997-10-23 Verbesserte adenovirusvektoren ATE466931T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/735,609 US5994132A (en) 1996-10-23 1996-10-23 Adenovirus vectors
PCT/US1997/019541 WO1998017783A1 (en) 1996-10-23 1997-10-23 Improved adenovirus vectors

Publications (1)

Publication Number Publication Date
ATE466931T1 true ATE466931T1 (de) 2010-05-15

Family

ID=24956492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97946337T ATE466931T1 (de) 1996-10-23 1997-10-23 Verbesserte adenovirusvektoren

Country Status (6)

Country Link
US (5) US5994132A (de)
EP (1) EP0935648B1 (de)
AT (1) ATE466931T1 (de)
AU (1) AU5152998A (de)
DE (1) DE69739870D1 (de)
WO (1) WO1998017783A1 (de)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US20060110798A1 (en) * 1995-06-07 2006-05-25 Graham Frank L Cells expressing recombinase useful for adenovirus vector production and control of gene expression
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
WO2000012740A2 (en) 1998-08-28 2000-03-09 Duke University ADENOVIRUSES DELETED IN THE IVa2, 100K AND/OR PRETERMINAL PROTEIN SEQUENCES
EP1141357A1 (de) * 1999-01-14 2001-10-10 Novartis AG Adenovirus vektoren, verpackungszellinien, zusammensetzungen, verfahren zur herstellung und verwendung davon
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
WO2000077256A1 (en) * 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 48 human secreted proteins
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
AU1453501A (en) * 1999-11-10 2001-06-06 Genzyme Corporation Ptp/dna polymerase cell line as packaging cell line for minimal adenoviral vectors
JP2003516743A (ja) * 1999-12-14 2003-05-20 ジェノボ， インコーポレイテッド 複製不能アデノウイルスの製造のための方法および組成物
US6867022B1 (en) * 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US6562955B2 (en) * 2000-03-17 2003-05-13 Tosoh Corporation Oligonucleotides for detection of Vibrio parahaemolyticus and detection method for Vibrio parahaemolyticus using the same oligonucleotides
ES2330615T3 (es) 2000-04-28 2009-12-14 Asklepios Biopharmaceutical, Inc. Secuencias de adn que codifican para minigenes de distrofina y metodos de uso de las mismas.
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
EP1287153B1 (de) 2000-05-31 2009-09-30 Human Gene Therapy Research Institute Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren
ATE373095T1 (de) * 2000-07-14 2007-09-15 Univ Michigan Mutierte muskelspezifische enhancer
EP1365794A2 (de) * 2000-07-21 2003-12-03 Lue, Tom Vorbeugung und behandlung von störungen der sexuellen erregbarkeit
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
EP2336339A3 (de) 2000-09-25 2011-09-14 The Regents of the University of Michigan Herstellung viraler vektoren
GB2368064B (en) * 2000-09-30 2002-11-13 Imp Cancer Res Tech DNA Element and Associated Protein
US6916635B2 (en) * 2000-10-02 2005-07-12 The Research Foundation Of State University Of New York Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
US6593145B2 (en) 2001-03-07 2003-07-15 The Texas A&M University System Density gradient solutions of metal ion chelate complexes
WO2002072790A2 (en) 2001-03-14 2002-09-19 Myriad Genetics, Inc Tsg101-gag interaction and use thereof
CA2442144A1 (en) * 2001-03-26 2002-11-21 The Board Of Trustees Of The Leland Stanford Junior University A helper dependent adenoviral vector system and methods for using the same
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
US6844192B2 (en) 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
US7449562B2 (en) * 2001-06-29 2008-11-11 Novartis Ag PERV screening method and use thereof
WO2003010306A1 (en) * 2001-07-23 2003-02-06 Onyx Pharmaceuticals, Inc. Viral mutants that selectively replicate in targeted human cancer cells
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
DE10150984A1 (de) * 2001-10-16 2003-04-17 Holm Per Sonne Verwendung des adenoviralen E2-late-Promotors
US20030108524A1 (en) * 2001-10-18 2003-06-12 Melissa Diagana Vectors for expressing multiple transgenes
EP1308517A1 (de) * 2001-10-31 2003-05-07 Aventis Pharmacueticals Products Inc. Vektoren für die Expression von mehrere Transgenen
AU2003201741A1 (en) 2002-01-09 2003-07-24 Yusuke Nakamura Cancer profiles
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
JP5213298B2 (ja) 2002-05-27 2013-06-19 ホルム，ペル・ゾンネ アデノウイルスおよびそれをコードしている核酸の新たな使用
US7803365B2 (en) * 2002-12-02 2010-09-28 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
WO2004050844A2 (en) * 2002-12-02 2004-06-17 Biovec Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2515916A1 (en) * 2003-02-25 2004-09-10 Biovec B.V. Therapeutic applications of thrombomodulin gene via viral and non-viral vectors
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
CA2546178A1 (en) 2003-11-14 2005-06-09 Per Sonne Holm New use of adenovirus and nucleic acids coding therefor
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
WO2005117990A2 (en) * 2004-04-20 2005-12-15 Duke University Compositions and methods for treatment of vascular grafts
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
AU2005294265A1 (en) 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
CA2587712C (en) * 2004-11-18 2013-02-12 National University Of Corporation Hiroshima University Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant
US8557969B2 (en) * 2004-12-01 2013-10-15 The Regents Of The University Of Michigan Compositions and methods for regulating cardiac performance
US8999944B2 (en) 2005-01-20 2015-04-07 University Of Rochester Thioredoxin interacting protein (TXNIP) as regulator of vascular function
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2814598A1 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2007047907A2 (en) * 2005-10-14 2007-04-26 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
CA2628221A1 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anti-frizzled receptor antibodies for treating cancer
CA2628255C (en) * 2005-10-31 2016-04-19 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2007150069A2 (en) 2006-06-23 2007-12-27 Myriad Genetics, Inc. Dpyd gene variants and use thereof
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
WO2008010991A2 (en) 2006-07-17 2008-01-24 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
WO2008030605A2 (en) * 2006-09-08 2008-03-13 The Regents Of The University Of Michigan Herv group ii viruses in lymphoma and cancer
WO2008108890A2 (en) * 2006-10-18 2008-09-12 University Of Rochester Conditionally replicating viruses for cancer therapy
WO2008092002A2 (en) * 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
DK2170384T3 (en) * 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
EP2604701B1 (de) 2007-07-06 2015-11-04 The Regents Of The University Of Michigan Rezidivierende Genfusionen bei Prostatakrebs
JP5406187B2 (ja) 2007-08-16 2014-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌の代謝プロファイリング法
WO2009048909A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
US8193151B2 (en) * 2008-04-25 2012-06-05 Northwestern University Methods for treating atrial or ventricular arrhythmias
US8518884B2 (en) 2008-04-25 2013-08-27 Northwestern University Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
BRPI0920743A2 (pt) 2008-10-01 2016-09-20 Quintessence Biosciences Inc ribonucleases terapeuticas
KR20110111474A (ko) 2009-01-09 2011-10-11 더 리젠츠 오브 더 유니버시티 오브 미시간 암에서의 반복적 유전자 융합체
WO2010107991A2 (en) 2009-03-18 2010-09-23 Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
CN106390107B (zh) 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US20110237461A1 (en) 2010-03-17 2011-09-29 The Regents Of The University Of Michigan Using phage epitopes to profile the immune response
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2012092341A1 (en) 2010-12-28 2012-07-05 University Of Rochester Methods of modifying insulin signaling using biliverdin reductase (bvr) and bvr derived peptides
US20140155469A1 (en) 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
WO2013001372A2 (en) 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
EA029234B1 (ru) 2011-07-06 2018-02-28 Сюкехусет Сёрланнет Хф Нацеленная на egfr терапия
LT2753346T (lt) 2011-09-07 2020-08-10 Mount Sinai School Of Medicine Ceramidazė ir ląstelių diferenciacija
CA2853379C (en) 2011-10-27 2020-11-24 Wellstat Ophthalmics Corporation Vectors encoding rod-derived cone viability factor
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
WO2014063155A1 (en) 2012-10-21 2014-04-24 University Of Rochester Thy1 (cd90) as a novel therapy to control adipose tissue accumulation
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
CA2891855A1 (en) 2012-12-21 2014-06-26 Sykehuset Sorlandet Hf Egfr targeted therapy of neurological disorders and pain
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP2992112B1 (de) 2013-04-22 2020-06-03 Icahn School of Medicine at Mount Sinai Mutationen in pdgfrb und notch3 als ursachen für autosomale dominante infantile myofibromatose
EP3777980B1 (de) 2013-10-29 2023-12-06 President and Fellows of Harvard College Nuclear factor erythroid 2-like 2 (nrf2) zur verwendung in der behandlung der altersbedingten makuladegeneration
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
AU2016205208A1 (en) 2015-01-09 2017-07-06 Etubics Corporation Methods and compositions for ebola virus vaccination
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
US10377801B2 (en) 2015-11-04 2019-08-13 Northwestern University Amelioration of chronic kidney disease
EP3371211B1 (de) 2015-11-04 2025-01-01 Icahn School of Medicine at Mount Sinai Rho-assoziierte proteinkinasehemmer zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
US10669320B2 (en) 2015-11-18 2020-06-02 The Regents Of The University Of Michigan Mps1 and KNL1 phosphorylation system
JP2019504631A (ja) * 2016-02-05 2019-02-21 ナント ホールディングス アイピー、エルエルシー 組換えｃｘａｄｒ発現のための組成物および方法
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
CN109890408A (zh) 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法
CA2971303C (en) 2016-06-21 2026-03-03 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
WO2018013509A1 (en) 2016-07-11 2018-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias
US11241436B2 (en) 2017-01-25 2022-02-08 Northwestern University Autophagy inducers for treatment of CNS conditions
US10815484B2 (en) 2017-11-22 2020-10-27 The Regents Of The University Of Michigan Compositions and methods for treating cancer
WO2019147921A1 (en) 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
EP3743102A1 (de) 2018-01-26 2020-12-02 Nantcell, Inc. Zusammensetzungen und verfahren zur kombination eines krebsimpfstoffs und einer immunologischen adjuvanten therapie
US20220184232A1 (en) * 2019-03-25 2022-06-16 The Regents Of The University Of California Methods of treating tnni3-mediated cardiomyopathy
MX2021014525A (es) * 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
EP3990000A1 (de) 2019-06-28 2022-05-04 Nantcell, Inc. Pharmazeutische zusammensetzungen zur verbesserung der phagozytose ohne entzündung
KR102371663B1 (ko) * 2020-01-21 2022-03-04 코오롱생명과학 주식회사 아데노바이러스 벡터
CN115244077B (zh) 2020-03-11 2025-04-29 南特细胞公司 蛋白质治疗剂
EP4127193A4 (de) * 2020-03-28 2024-05-01 Greffex, Inc. Aufrechterhaltung von dna-fragmenten in eukaryotischen zellen, ansätze und verwendungen
AU2021254753A1 (en) 2020-04-14 2022-08-25 Nantcell, Inc. Yeast lysate COVID-19 vaccine
WO2022035863A1 (en) 2020-08-11 2022-02-17 Musculoskeletal Transplant Foundation Method for treating cardiac conditions with placenta-derived compositions
WO2022034523A1 (en) 2020-08-13 2022-02-17 Immunitybio, Inc. Phagocytosis-inducing compounds and methods of use
CN117715929A (zh) 2021-07-29 2024-03-15 南特细胞公司 用于预防和治疗病毒感染和癌症的经修饰的t细胞受体
EP4335870A1 (de) 2022-09-06 2024-03-13 NantCell, Inc. Peptidtherapeutika gegen das sars-cov-2-spike-protein
KR20260008735A (ko) 2023-03-30 2026-01-16 파마 싱크, 엘엘씨 간상체-유래 원뿔세포 생존인자 및 인간 IgK 신호 서열을 인코딩하는 벡터
WO2026006370A1 (en) 2024-06-28 2026-01-02 Immunitybio, Inc. Anti-slamf7 antibodies and therapeutics
GB202410992D0 (en) * 2024-07-26 2024-09-11 Icosphere Biosciences Ltd Process for making gutless helper-dependent adenoviruses
US20260091133A1 (en) 2024-09-27 2026-04-02 Pharma Cinq, Llc Rod-derived cone viability factor fusion protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE69534166T2 (de) * 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
AU5551996A (en) 1995-04-17 1996-11-07 Board Of Regents, The University Of Texas System An adenovirus helper-virus system
AU2319497A (en) * 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy

Also Published As

Publication number Publication date
EP0935648A1 (de) 1999-08-18
WO1998017783A1 (en) 1998-04-30
EP0935648A4 (de) 2004-11-17
US6057158A (en) 2000-05-02
DE69739870D1 (de) 2010-06-17
US6083750A (en) 2000-07-04
US5994132A (en) 1999-11-30
AU5152998A (en) 1998-05-15
US6451596B1 (en) 2002-09-17
US6063622A (en) 2000-05-16
EP0935648B1 (de) 2010-05-05

Similar Documents

Publication Publication Date Title
ATE466931T1 (de) Verbesserte adenovirusvektoren
ES2151310T3 (es) Nuevas lineas celulares de complementacion para vectores adenovirales defectivos.
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
DE69820450D1 (de) Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
EP0710288A4 (de) Adenovirale vektoren für die behandlung der hämophilie
WO2000012740A3 (en) Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
CA2161962A1 (en) Adenovirus vectors for gene therapy
MX9702553A (es) Adenovirus libres de particulas contaminantes viables, su preparacion y su uso.
WO2001036615A3 (de) Permanente amniozyten-zelllinie, ihre herstellung und verwendung zur herstellung von gentransfervektoren
AU2812484A (en) Dna vectors and there use in recombinant dna technology
CA2104396A1 (en) Viral particles having altered host range
CA2236968A1 (en) Accessory functions for use in recombinant aav virion production
JP2003514526A5 (de)
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
ATE403736T1 (de) Onkolytische adenovirale vektoren
AUPN477695A0 (en) Gene therapy
DE69628744D1 (de) Adenovirus helfervirus system
IL128635A0 (en) Herpesvirus saimiri as viral vector
AU5318496A (en) Adenovirus vectors for gene therapy
WO2004018627A3 (en) Methods for propagating adenovirus and virus produced thereby
Kaplan et al. Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes
BR9806084A (pt) Vetor de poliovirus sabin tipo i, recombinante ou quimérico de replicação competente, seus métodos de produção e célula hospedeira
SE8604636D0 (sv) Sett att uttrycka gener med hjelp av bacillus brevis
WO2000022136A3 (en) Recombinant e1a deleted adenoviral vectors
WO2000029573A3 (en) Adenoviral vectors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties